Molecular Partners Ag (MOLN) Liabilities and Shareholders Equity (2020 - 2026)

Molecular Partners Ag (MOLN) has reported Liabilities and Shareholders Equity for 7 consecutive years, with $111939.7 the latest figure, recorded in Q1 2026.

• Quarterly Liabilities and Shareholders Equity fell 100.0% year-over-year to $111939.7 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $252417.3 (down 100.0% YoY) and the FY2025 annual result came in at $127.75, down 100.0% from the prior year.
• Liabilities and Shareholders Equity grew to $111939.7 in Q1 2026 per MOLN's latest filing, from $127.75 in the prior quarter.
• Over the last five years, Liabilities and Shareholders Equity for MOLN reached as high as $337.7 billion in Q1 2022 and fell as low as $127.75 in Q4 2025.
• A 5-year average of $99.4 billion and a median of $272.2 million in 2022 frame the typical range for Liabilities and Shareholders Equity.
• Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity soared 51.57% — and 2025, when it sank 100.0%.
• Year by year, Liabilities and Shareholders Equity stood at $272.2 million in 2022, then slipped by 17.86% to $223.6 million in 2023, then retreated by 19.07% to $181.0 million in 2024, then plunged by 100.0% to $127.75 in 2025, then surged by 87521.82% to $111939.7 in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $111939.7, $127.75, and $140199.8 for Q1 2026, Q4 2025, and Q3 2025 respectively.